AM1710 Worked in One Mouse Neuropathy Model but Failed in Two Other Pain Models
A cannabinoid-related pain finding can be positive in one disease model and negative in another. AM1710 suppressed paclitaxel-related allodynia in mice but did not suppress the tested inflammatory or nerve-ligation allodynia.
Several models tested the same broad claim
The research combined receptor-signaling assays in engineered cells with mouse experiments. In the cell studies, AM1710 affected cAMP and kinase signaling. In animals, investigators compared chemotherapy-related neuropathy with inflammatory and partial sciatic nerve-ligation models.
The negative models were not omitted
The abstract reports sustained benefit in the paclitaxel model, but no suppression of established allodynia in the other two models. Gabapentin did suppress allodynia in those comparison models. Preventive and repeated AM1710 dosing also lacked efficacy in the reported inflammatory model.
An active comparison strengthens interpretation
When another treatment works in a model, a negative experimental-drug result is harder to dismiss simply as an inability to detect any treatment effect. That does not establish absolute ineffectiveness under every possible dose or regimen, but it bounds the broad-spectrum analgesic claim.
AM1710 also affected later morphine tolerance and dependence-related outcomes in paclitaxel-treated mice. Those results do not convert its negative findings in other models into positives. Receptor selectivity, disease mechanism and the particular outcome all matter. This experimental agonist should not be relabeled as THC, CBD or evidence that cannabis treats every kind of pain.
Related: interpreting cannabis tolerance claims.
Research cited
Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Molecular pharmacology (2019). doi:10.1124/mol.118.113233. Findings discussed from the study abstract.
